ABUS—…AB-836 results seem in the same ballpark as [ENTA’s] edp-514. Am I reading that right?I don’t think it’s reasonable to reach such a conclusion. ABUS’ 12/1/21 PR (https://investor.arbutusbio.com/news-releases/news-release-details/preliminary-data-shows-arbutus-capsid-inhibitor-ab-836-generally ) offered very little actual data on the phase-1b trial.